



PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031


**U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE**

**Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.**

Substitute for form 1449A/PTO				Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				<i>TECH-GEN</i>	
(use as many sheets as necessary)					
Sheet	1	of	2	Application Number	09/902,176
				Filing Date	July 10, 2001
				First Named Inventor	Schreiber
				Art Unit	1645
				Examiner Name	Not yet assigned
				Attorney Docket Number	25481-P001US

## **U.S. PATENT DOCUMENTS**

## FOREIGN PATENT DOCUMENTS

Examiner Signature		Date Considered	6/16/05
-----------------------	---	--------------------	---------

**\*EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



PTO/SB/088 (10-01)  
Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 2

### Complete if Known

Application Number	09/902,176
Filing Date	July 10, 2001
First Named Inventor	Schreiber
Group Art Unit	1645
Examiner Name	Not yet assigned
Attorney Docket Number	25481-P001US

RECEIVED  
JAN 29 2002  
TECH CENTER 1600/2900

### OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS


Examiner Initials	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
SP		SMITH et al.; Human Tumor Necrosis Factor Receptor mRNA; Database EMHUM6 'Online!'; ID HSNFR, June 1990	
		SYNERGEN, Inc.; 40kD TNF Inhibitor Precursor; Database GCG_GENESEQ_P 'Online!'; R11001 January 1991	
		SMITH; Fibroblast Derived TNF-R; Database GCG_GENESEQ_P 'Online!'; ID: R42058, April 1994	
		BELTINGER, et al.; Physical Mapping and Genomic Structure of the Human TNFR2 Gene; Genomics 35, 94-11 (1996); Article No. 0327; 1996	
		RAU, et al.; Polymorphisms of Tumor Necrosis Factor Receptor 2 are Not Associated with Insulin-Dependent diabetes Mellitus or Graves' Disease; Tissue Antigens; Vol 49, No. 5, 1997, pages 535-536	
		VAN DEVENTER; Immunomodulation of Chron's Disease Using TNF-alpha Neutralizing Monoclonal Antibodies; Clinical Nutrition, GB, Churchill, Livingston, London; 1997	
		CHO, et al.; Identification of Novel Susceptibility Loci for Inflammatory Bowel disease on Chromosomes 1p, 3q, and 4q: Evidence for Epistasis Between 1p and IBD1; Proceedings of the National Academy of Sciences of the United States; vol 95, no. 13; June 23, 1998; pages 7502-7507	
		KOMATA, et al.; Association of Tumor Necrosis Factor Receptor 2 (TNFR2) Polymorphism with Susceptibility to systemic Lupus Erythematosus; Tissue Antigens, Vol 53, No. 6; June 1999; pages 527-533	
		PANTELIDIS, et al.; Polymorphic Analysis of the High-Affinity Tumor Necrosis Factor Receptor 2; Tissue Antigens, Vol 54, Dec. 1999; pages 585-591	
		AL-ANSARI, et al.; Tumor Necrosis Factor Receptor II (TNFRII) Exon 6 Polymorphism in systemic Lupus Erythematosus; Tissue Antigens, Vol 55, No. 1; January 2000, pages 97-99	
		LOUIS, et al.; Tumour Necrosis Factor (TNF) Gene Polymorphism in Crohn's Disease (CD): Influence on Disease Behaviour?; Clinical and Experimental Immunology, Vol 119, No. 1, January 2000; pages 64-68	

Examiner Signature		Date Considered	10/16/05
--------------------	--	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 509. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



PTO/SB/08B (04-03)

Approved for use through 04/30/2003. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

of

Complete If Known

Application Number	09/902,176
Filing Date	July 10, 2001
First Named Inventor	Stefan Schreiber
Art Unit	1634
Examiner Name	Sally A. Sakelaris
Attorney Docket Number	25481-P001US

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
SS		ELLIOT, et al; Randomized double blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 344:1105-1110, 1994. <i>IN IDS# 1214704 DUPLICATE</i>	
		FABRIS, et.al.; Tumor Necrosis Factor-alpha Receptor II Polymorphism in Patients from Southern Europe with Mild-Moderate and Severe Rheumatoid Arthritis; <a href="http://www.jrheum.com/subscribers/02/09/1847.html">http://www.jrheum.com/subscribers/02/09/1847.html</a> ; December 14, 2004 " DUPLICATE	
		OGILVIE, et al.; Treatment of psoriatic arthritis with antitumour necrosis factor-alpha antibody clears skin lesions of psoriasis resistant to treatment with methotrexate; British Journal of Dermatology 2001; 144: 587-589; UK " DUPLICATE	
		YEE, et al.; Treatment of Complicated Sarcoidosis with Infliximab Anti-tumor Necrosis Factor-Alpha Therapy; Annals of Internal Medicine; <a href="http://www.annals.org/cgi/content/full/135/1/27">http://www.annals.org/cgi/content/full/135/1/27</a> ; December 14, 2004 " DUPLICATE	
		ARINGER, et al.; Safety and Efficacy of Tumor Necrosis Factor Alpha Blockade in Systemic Lupus Erythematosus; Arthritis & Rheumatism; American College of Rheumatology; Vol. 50, No. 10, October 2004; pp 3161-3169; US " DUPLICATE	
SS		RUTGEERTS, et.al.; Treatment of active Crohn's diseases with oncept (recombinant human soluble p55 tumour necrosis factor receptor); results of a randomized, open-label, pilot study; Alimentary Pharmacology & Therapeutics; Volume 17, Issue 2, Page 185, January 2003; <a href="http://www.blackwell-synergy.com/links/doi/10.1046/j.1365-2036.2003.01414.x/full/">http://www.blackwell-synergy.com/links/doi/10.1046/j.1365-2036.2003.01414.x/full/</a> " DUPLICATE	

Examiner Signature		Date Considered	6/16/05
--------------------	--	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.